Immuno-Biological LaboratoriesImmuno-Biological Laboratories Co., Ltd.4570東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP

What does Immuno-Biological Laboratories do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income¥329M

Operating cash flow¥301.1M

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow¥301.1M

Free cash flow¥267.7M

Net income¥329M

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第44期(2025/04/01－2026/03/31)
ID S100YLCK2026-06-26Open
EDINET (FSA Japan)
有価証券報告書－第43期(2024/04/01－2025/03/31)
ID S100W7T72025-06-27Open
EDINET (FSA Japan)
有価証券報告書－第42期(2023/04/01－2024/03/31)
ID S100TTJJ2024-06-26Open
EDINET (FSA Japan)
有価証券報告書－第41期(2022/04/01－2023/03/31)
ID S100R9RY2023-06-30Open
EDINET (FSA Japan)
有価証券報告書－第40期(令和3年4月1日－令和4年3月31日)
ID S100OIQD2022-06-30Open
EDINET (FSA Japan)
訂正有価証券報告書－第39期(令和2年4月1日－令和3年3月31日)
ID S100N41B2021-12-22Open

Extracted from XBRL: 46 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.